Akero Therapeutics To Present At The Jefferies Global Healthcare Conference [TheStreet.com]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: TheStreet.com
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 4:00 p.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website at. Following the live webcasts, archived replays will be available on the Company's website. About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), is a differentiated Fc-FGF21 fusion protein that has been eng
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Akero Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – AKROAccesswire
- Akero Therapeutics Class Action Investigation: Johnson Fistel has Commenced an Investigation on Behalf of Akero Therapeutics ShareholdersGlobeNewswire
- Akero Therapeutics, Inc. (AKRO) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky InvestigatesAccesswire
- Shareholder Rights Advocates at Levi & Korsinsky Investigate Akero Therapeutics, Inc. (AKRO) Regarding Possible Securities Fraud ViolationsAccesswire
- AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)GlobeNewswire
AKRO
Earnings
- 11/13/23 - Miss
AKRO
Analyst Actions
- 3/5/24 - UBS
AKRO
Sec Filings
- 3/18/24 - Form 8-K
- 3/15/24 - Form 4
- 3/15/24 - Form 4
- AKRO's page on the SEC website